Kornimate/medical-research-clean huggingface dataset:
a trial of shr0410 injection in hemodialysis participants.

Conditions: Pruritus

Summary: this is a multi-site study to evaluate the safety and pharmacokinetics of repeated doses of iv shr0410 in participants who are undergoing hemodialysis.

this is a multi-site study to evaluate the safety and pharmacokinetics of repeated doses of iv shr0410 in participants who are undergoing hemodialysis. twenty-four eligible participants will be enrolled into 3 dose cohorts. shr0410 will be administered after dialysis session. safety assessments, pk assessments and efficacy evaluations will be performed.

Eligibility criteria:
inclusion criteria: * able to understand the study procedures, the risks involved and obtain written informed consent before any study related activity. * male or female between the ages of 18 and 75 years, inclusive. * male subjects with a partner of childbearing potential must be willing to use a condom when sexually active, throughout the study period and for 28 days following last study drug dosing. female subjects must be post-menopausal for at least 1 year, permanently sterilized (e.g., tubal occlusion, hysterectomy, bilateral salpingectomy) or, if of childbearing potential, must be willing to use a highly effective method of contraception throughout the study period and for 28 days following last study drug dosing. * negative drug screen (including alcohol, amphetamines, cocaine, marijuana, opiates, phencyclidine, barbiturates, benzodiazepines, methadone, methamphetamines, tramadol, and tricyclic antidepressants) at screening and on admission to study site. exclusion criteria: * anticipated to receive a kidney transplant during the study. * known history of allergic reaction to opiates such as hives (note: side effects related to the use of opioids such as constipation or nausea would not exclude the participants from the study). * within 12 months prior to screening, known or suspected history of drug abuse or dependence according to diagnostic and statistical manual of mental disorders, fifth edition (dsm-5).
efficacy and safety of peg 3350 for treatment of chronic constipation

Conditions: Constipation - Functional

Summary: the aim of this study is to determine the efficacy and safety of peg 3350 (polyethylene glycol 3350) for short-term treatment of chronic constipation in adults.


Eligibility criteria:
inclusion criteria: 1. males and females aged ≥ 18 years. 2. body mass index (bmi) ≥ 18.5 3. organic bowel disease will be ruled out by fecal immunochemical test (fit) and/or colonoscopy. 4. must have ≤ 2 bowel movements during a 7-day qualification period. 5. in otherwise good health as judged by a physical examination and laboratory testing. 6. not taking medications known to affect bowel function in one week before study. 7. willing to participate in the study by signing the informed consent. exclusion criteria: 1. hypersensitive to the study medication. 2. obstructive ileus. 3. irritable bowel syndrome (ibs) or inflammatory bowel disease (ibd)

Keywords: peg 3350 constipation
a study of pegasys (peginterferon alfa-2a (40kd)) in combination with ribavirin in patients with chronic hepatitis c (chc) previously treated with peg-intron + ribavirin

Conditions: Hepatitis C, Chronic

Summary: this study will evaluate the efficacy, safety and tolerability of pegasys plus ribavirin in patients with chc who could not tolerate or were not responsive to 12 weeks of therapy with peg-intron plus ribavirin. the anticipated time on study treatment is 1-2 years, and the target sample size is \>100 individuals.


Eligibility criteria:
inclusion criteria: * adult patients at least 18 years of age * chc infection, genotype 1 * unable to tolerate or not responsive to peg-intron + ribavirin therapy after 12 weeks of treatment * use of 2 forms of contraception during the study in both men and women exclusion criteria: * women who are pregnant or breast-feeding * medical condition associated with chronic liver disease (eg, hemochromatosis, autoimmune hepatitis, alcoholic liver disease, toxin exposures) * patients with decompensated cirrhosis * patients receiving any systemic antiviral therapy or investigational drug, other than peg-intron + ribavirin, 24 weeks prior to the first dose of study drug
the effects of flaxseed supplement on weight and biochemical factors in overweight and obese subject

Conditions: Overweight and Obesity

Summary: to study the effects of flaxseed supplement on weight, lipid profile and inflammatory factors in subjects with over weight and obesity, 50 patients will be randomly allocated to receive placebo or 30 grams milled flaxseed for 12 weeks; both groups will be advised to adherence the investigators' diet and exercise program too. at the first and the end of the intervention, weight, waist and hip circumference, lipid profile and some inflammatory markers will be assessed and compared between groups.


Eligibility criteria:
inclusion criteria: * age of 18 to 70 years * body mass index (bmi) between 25-40 exclusion criteria: * diabetes mellitus * cardiovascular diseases and cancers * major systemic diseases * gastrointestinal problems * liver and renal failure * history of allergy or high consumption of nuts, flaxseed, or sesame seeds * weight loss within the past 6 mo of \>5% of body weight or current adherence to a weight-reduction diet * pregnancy, lactation
triamcinolone ketorolac (trike) knee trial

Conditions: Osteoarthritis, Knee

Summary: cortisone injections are commonly used in the treatment of osteoarthrosis of the knee, but there are known detriments to cortisone including localized tissue atrophy near the injection site and acceleration of joint degeneration, as well as contraindications, such as uncontrolled diabetes. ketorolac is a non-steroidal anti-inflammatory with decades of clinical data that is most commonly injected intramuscularly. there is rising interest in using ketorolac as an intra-articular injectant substitute or adjunctive to cortisone. this may potentially improve clinical outcomes or decrease adverse effects. although intra-articular use of ketorolac is increasing in orthopedics and sports medicine, there is limited data in the literature comparing these two injectants in prospective, randomized trials, and no data that evaluates combining the two injectants. primary objectives are to evaluate the efficacy of intra-articular ketorolac compared to cortisone on knee osteoarthrosis and to evaluate whether the combination of ketorolac and cortisone is superior to either alone.

charts will be prescreened for diagnosis or suspicion of osteoarthritis of the knee by the study staff. those charts identified will be flagged for possible inclusion in the study. the receptionist will give the prospective subject a copy of the consent to read while they are in the waiting room. once they are taken back to the room, the investigator will review the study with them. if they are agreeable, they will sign the consent and a copy will be given to them and a copy will be scanned into the electronic medical record (emr). the investigator will then notify the unblinded investigator, who will randomize the subject and prepare the medication in a blinded fashion. the subject will receive either ketorolac 30 mg, triamcinolone 40 mg, or a combination of the two medications as a one-time injection into the affected knee joint/s. the subject will be asked to complete a survey prior to receiving the injection, and again at 1 week, 6 weeks, and 12 weeks post injection. if necessary, an additional survey will be completed at 24 weeks post injection.

Eligibility criteria:
inclusion criteria: * knee pain with diagnosis of osteoarthritis/osteoarthrosis * weight-bearing x-rays within the last year adequate to assess kellgran-lawrence oa stage * age \> 21 * english proficiency sufficient to complete surveys * willing to complete follow-up surveys exclusion criteria: * prior knee injection in last 3 months * knee surgery within the last year * contraindications to cortisone, ketorolac, or local anesthetic * uncontrolled diabetes * systemic steroid use in last 3 months * bmi \> 50 * non-ambulatory * known kidney disease * current opioid use
the effect of 21-days intranasal oxytocin on patients with post traumatic stress disorder (ptsd)

Conditions: PTSD

Summary: oxytocin (ot) - a neurohormone and neuromodulator which is mainly synthesized in the hypothalamus - is a mediator stress regulation and improves social bonding. recently, several theoretical studies suggested that ptsd patients have abnormal functioning of the ot system. according to these theories, dysfunction in the oxytocin system may modulate the interpersonal impairment that characterizes ptsd, and therefore intranasal ot may potentially relieve these symptoms. in two current studies that were conducted in rambam health care we found that a single dose of intranasal ot reduces anxiety and irritability symptoms, and enhances emotional empathy and compassion, in patients with ptsd. the main goal of this study is to examine the effects of 21-days intranasal oxytocin on clinical symptoms and social function in these patients.

this study will examine the effect is of 21-days intranasal oxytocin on clinical symptoms and social function in these patients, in a double blind (treatment/placebo) study design.

Eligibility criteria:
inclusion criteria: * ptsd patients (dsm-iv criteria) * ability to provide written informed consent exclusion criteria: * suicidality * psychosis * borderline personality * arrhythmia * cardiac disease (arrythmia, heart failure) * hyponatremia * hypertension * severe renal insufficiency * liver cirrhosis * lactating or pregnant women, or undergoing fertility treatment

Keywords: ptsd, oxytocin
evaluation of dalteparin for long-term (one year) treatment of blood clots in subjects with cancer

Conditions: Cancer

Summary: the purpose of this study is to determine the long term tolerability and safety of dalteparin in subjects with cancer.


Eligibility criteria:
inclusion criteria: 1. male and female subjects, age greater than or equal to 18 years of age. 2. females should be either of non-childbearing potential as a result of surgery, radiation therapy, menopause (one year post onset), or of childbearing potential and willing to adhere to an acceptable method of pregnancy prevention. 3. subjects must be newly diagnosed, symptomatic proximal deep-vein thrombosis of the lower extremity, pulmonary embolism, or both. 4. subjects must have active malignancy defined as a diagnosis of cancer (excluding basal cell or squamous cell carcinoma of the skin) within six months before enrollment, having received any treatment for cancer within the previous six months, or having documented recurrent or metastatic cancer. 5. prior to enrollment, subjects must not have received therapeutic doses of anticoagulant therapy (including low molecular weight heparin \[lmwh\]) for \>48 hours (or \>4 doses within 48 hours). 6. eastern cooperative oncology group (ecog) performance status of 0, 1 or 2. 7. subjects must have a life expectancy of \>6 months. 8. subjects must have a platelet count of \>75,000 mm\^3. 9. the subject must not be on any oral anticoagulant therapy for concomitant diseases. 10. subjects must have no active or serious bleeding episodes within two weeks prior to study entry. 11. subjects must be able to comply with scheduled follow-ups. exclusion criteria: 1. subjects who have a high risk of serious bleeding (e.g., recent neurosurgery within 30 days, history of intracranial hemorrhage, acute gastroduodenal ulcer, etc.). 2. subjects who are on hemodialysis. 3. subjects who have a prior placement of a greenfield filter or other device to prevent embolization of deep vein thromboses. 4. subjects with a known contraindication to the use of heparin (e.g., heparin-induced thrombocytopenia). 5. subjects with a known hypersensitivity to heparin, dalteparin sodium, other lmwhs or pork products. 6. subjects who are currently participating in another clinical trial involving anticoagulation therapy (with the exception of acetylsalicylic acid (asa) in the 30 days prior to study entry, or who are actively using any investigational drugs/treatments 30 days prior to study entry involving anticoagulation therapy (with the exception of asa , t.i.d). 7. subject is pregnant or breast feeding. 8. subjects with uncontrolled hypertension characterized by a sustained systolic pressure \>170 mmhg and/or diastolic pressure \>100 mmhg. 9. subjects with a serious concomitant systemic disorder (for example, active infection including hiv or cardiac disease) that in the opinion of the investigator, would compromise the subject's ability to complete the study. 10. any condition that makes the subject unsuitable in the opinion of the investigator. 11. subjects with leukemia or myeloproliferative syndrome.
delirium screening, incidence and management observational study in 2024 - the czech republic

Conditions: Delirium

Summary: delirium in intensive care unit (icu) settings is a frequent complication with reported prevalence of 31%. recent data has revealed the connection between delirium and increased 30days mortality after hospital release and the higher incidence of readmission to emergency. despite the high prevalence and well described validation methods for screening, the precise incidence remains unclear due to insufficient screening in icu settings. the incidence of delirium in czech republic remains undescribed, beside data reported from neurointensive care patients and single-center general critically ill patients data.

all patients fulfilling inclusion criteria in intensive care settings in involved icus in czech republic will be included into the study. data will be recorded for 1 consequent month. basic demography will be evaluated. in each patient standard delirium screening based on the institutional icu rules will be performed. if no screening method were set,confusion assessment method - cam-icu for adult and pediatric confusion assessment method -pcam-icu for pediatric patients would be used together with delirium management, restrain procedures, sedative/neuroleptics administration, 28-days mortality. all data will be recorded into to predefined ecrf.

Eligibility criteria:
inclusion criteria: * patients in icu settings * in defined time interval of the study exclusion criteria: * duration of icu stay shorter than 24 hours

Keywords: delirium screening therapy cam-icu
balance trainning for sarcopenic inpatients aged 80+ years

Conditions: Sarcopenia

Summary: resistance training and aerobic exercise have been recommended for sarcopenic patients. however, whether balance training would further benefit for sarcopenic patients on the basis of resistance training and aerobic exercise remains unclear. the purpose of this study is to explore the effect of balance training on improving the mobility of elderly patients with sarcopenia. balance training involves doing exercises that strengthen the muscles that help keep the aged upright, including the legs and core. these kinds of exercises can improve stability and help prevent falls.


Eligibility criteria:
inclusion criteria： * sarcopenia defined by the asia working group of sarcopenia (awgs) * agree to participant this study and sign the informed consent * aged 80 years or over exclusion criteria: * patients who could not follow the training plan due to cognitive impairment, emotional problems or any other reasons; * severe heart and lung diseases; * renal insufficiency; * any type of tumor; * bedridden patients
virtual reality and active video games to improve balance in children with brain injury

Conditions: Cerebral Palsy; Acquired Brain Injury

Summary: the purpose of this pilot feasibility study is to assess the feasibility of using the playstation xbox 360 and rutgers v-step via a kinect sensor with active video game software as a part of a physical therapy intervention to improve obstacle negotiation, gait speed, and stair negotiation in ambulatory children with cerebral palsy (cp) hemiparesis or spastic diplegia, or non-progressive brain injury (bi). children will be assessed using perceptual, balance, functional and gait assessments.


Eligibility criteria:
inclusion criteria: * age 7-17 * diagnosis of cerebral palsy or diagnosis of acquired brain injury * ambulatory with or without an assistive device x 150 feet * cognition and attention ability sufficient to be successful in video game play and to follow instructions of the investigator. * able to complete testing process. * current patient at blythedale children's hospital program (expected length of stay/availability for study of approximately 8 weeks) exclusion criteria: * any history of photosensitive epilepsy or seizures triggered by exposure to flashing lights, television or video games * attention or behavior problems that prevent the successful completion of game play * any acute musculoskeletal injury that limits weight bearing on one lower extremity (due to orthopedist concerns for fracture or injury) * any medical condition that prevents the child from tolerating exercise due to cardiovascular conditions

Keywords: virtual reality hemiplegia diplegia video gaming active video games playstation x-box 360 rutgers v-step microsoft kinect
effect of the minimum bronchial cuff volume of left-sided double-lumen endotracheal tube for one-lung ventilation on the change of the bronchial cuff pressure during lateral positioning in thoracic surgery

Conditions: Lung Cancer; Pneumothorax

Summary: over-inflation of the bronchial cuff of the double-lumen tube (dlt) can cause damage to the airway mucosa and misplacement of the tube, and under-inflation may cause incomplete collapse of the non-ventilated lung and incomplete ventilation of the lung that should be ventilated. appropriate cuff pressure is generally known to be ranged 20-30 cmh₂o, but in the study of okubo et al., who observed the minimum bronchial cuff volume and pressure that did not cause air leakage using the method of confirming by capnography, it was possible to obtain the result that olv was possible without air leakage even at a pressure lower than 25 cmh₂o (the generally recommended tube cuff pressure) in both men and women. in a recent study of yamada et al., when using the capnography waveform-guided method to inflate the bronchial cuff by checking for air leakage using the capnography waveform, the bronchial cuff volume (bcv) that satisfies the air-tight seal was significantly smaller compared with a pressure-guided method to inflate the bronchial cuff with 20 cmh₂o. the minimum bronchial cuff volume (bcvmin) at which such air leakage does not occur may vary from individual to individual. it is presumed that this is because the diameter of the left main bronchus (lmb) differs from individual to individual, which causes the variation of the gap between the diameter of the lmb and the outer diameter of the dlt mounted thereon. moreover, the previous study revealed that the lateral positioning could increase the pressure of the bronchial cuff mounted on the lmb due to the gravity-induced morphological and conformational change of the trachea. considering these factors, the researchers hypothesized that the change in the bronchial cuff pressure (bcp) due to a positional change might vary depending on whether the bronchial cuff was inflated, that is, the initially established bcvmin. therefore, in this study, the researchers tried to investigate the effect of bcvmin on the change of minimum bronchial cuff pressure (bcpmin) due to the positional change from the supine to lateral decubitus, by dividing the groups whose bcvmin is 0 ml or exceeds 0 ml.


Eligibility criteria:
inclusion criteria: patients aged 18-80 and with an american society of anesthesiologists (asa) physical status of 1 or 3 who are scheduled to undergo elective video-assisted thoracoscopic surgery (vats) exclusion criteria: a. need for a right-sided dlt b. an intraluminal lesion in the left main bronchus c. an anatomical problem in the tracheobronchial tree d. patients with chronic obstructive pulmonary disease with impaired lung compliance e. patients with interstitial lung disease with severe pulmonary dysfunction f. patients with body mass index (bmi) ≥ 30

Keywords: cuff pressure double lumen endotracheal tube lateral positioning
early detection of lung cancer and mesothelioma in workers exposed to asbestos

Conditions: Mesothelioma; Lung Cancer

Summary: this is a pilot study that aims to develop a lung cancer screening program for workers in british columbia, canada exposed to asbestos who are at risk of developing lung cancer/pleural mesothelioma. this is high risk population is at of respiratory system diseases as a result of their occupational exposures. additionally, knowledge garnered from this study will allow us to develop other studies that will further our understanding of asbestos related lung cancer and mesothelioma.


Eligibility criteria:
inclusion criteria: * women or men age 50 to 79 years * history of exposure to asbestos at work and one or more of the following: * lung cancer risk ≥2% over 3 years or * asbestosis or pleural plaques on a chest x-ray or * abnormal auto-antibodies level using the earlycdt test * capable of providing informed consent for screening procedures (low dose spiral ct, lung function, blood biomarkers). exclusion criteria: * any medical condition, such as severe heart disease (e.g. unstable angina, chronic congestive heart failure), acute or chronic respiratory failure, or any disorder, that in the opinion of the physician unlikely to benefit from screening due to shortened life-expectancy from co-existing illnesses * have been previously diagnosed with mesothelioma * have had other cancer within the past 5 years with the exception of the following cancers: non-melanomatous skin cancer,localized prostate cancer, carcinoma in situ (cis) of the cervix, or superficial bladder cancer. treatment of the exceptions must have ended \>6 months before registration into this study * pregnancy * unwilling to have a low dose ct scan of chest * unwilling to sign a consent

Keywords: mesothelioma lung cancer early detection
diffusion tensor imaging magnetic resonance imaging (dti mri) as a correlate to pain relief and facial numbness in patients following stereotactic radiosurgical rhizotomy for trigeminal neuralgia

Conditions: Trigeminal Neuralgia

Summary: trigeminal neuralgia or tic douloureux is severe, often debilitating, facial pain that significantly impairs the patient's quality of life and health. stereotactic radiosurgery has been shown to provide pain relief in majority of patients treated. however, a common side effect of radiosurgery is facial numbness. to better understand how radiosurgery can bring about pain relief and facial numbness, we are conducting a study in which brain mri scans will be done following stereotactic radiosurgery to learn if there are any changes in the mri scans that correlate with symptoms.


Eligibility criteria:
inclusion criteria: * all patients age 18 years and older with typical trigeminal neuralgia, as determined by diagnostic criteria set by the international headache society, who are 1) intolerant of or refractory to medical management and 2) not candidates for or refusing a surgical micro-vascular decompression, will be evaluated for treatment with srs. * ecog or karnofsky performance status will not be employed, but patients must be sufficiently healthy to tolerate all study procedures. * patient must exhibit the ability to understand and the willingness to sign a written informed consent. exclusion criteria: * exclusion criteria * patients who present with pre-existing facial numbness. * patients mri contraindications (e.g., pacemaker or defibrillator, cochlear implant, brain aneurysm clip, etc.) * patients who have previously been treated with mvd. * patients who have previously had an ablative treatment, including prior srs. * pediatric patients (age \<18), pregnant women, and patients who are unable to give informed consent will be excluded.